生物活性 | |||
---|---|---|---|
描述 | Benorylate (4-acetamidophenyl 2-acetoxybenzoate) is a new esterified aspirin preparation whose antirheumatic properties are reported to be as good as those of aspirin[3]. Benorylate (Salipran) causes a large decrease in the liver’s conversion rate of lactate into glucose, an important component of glucose homeostasis. Benorylate (Salipran) also impairs the urea synthesis rate from ammonia, another important function of the liver[4]. Benorylate is probably absorbed as the intact molecule which accounts for its good gastric tolerance. After absorption, benorylate is hydrolysed into its components, salicylate and paracetamol, which then follows the usual routes of metabolism[5]. Benorylate 4 g twice daily was shown to be an effective analgesic and anti-inflammatory drug, its effects being indistinguishable from those of aspirin 1.2 g four times daily. The overall incidence of side effects was less with benorylate, though this difference was not significant at the 5% level[6]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
3.19mL 0.64mL 0.32mL |
15.96mL 3.19mL 1.60mL |
31.92mL 6.38mL 3.19mL |
参考文献 |
---|
[5]Wright V. A review of benorylate - a new antirheumatic drug. Scand J Rheumatol Suppl. 1975;13:5-8 |